Press Release 10 December 2021 14:00:00 CET



## Newbury Pharmaceuticals is strengthening its oncology portfolio

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the oncology portfolio with the addition of Lapatinib. Lapatinib is a targeted cancer drug, also known by its brand name Tyverb®, that is used to treat certain type of breast cancers, whose tumours overexpress HER2.

"Lapatinib is a terrific supplement to the existing high-value product portfolio and we are proud to further strengthen our commitment within oncology" says Mr Lars Minor CEO of Newbury

Newbury currently has eleven (11) products within oncology and providing treatment options for both solid and hematological malignancies (e.g. breast cancer, myeloma, leukemia, prostate cancer, NSCLC and thyroid cancer).

Regulatory filling will take place during the next few years, and we aim to be among the first to launch many of these medicines in Scandinavia where the total annual value of this market is estimated to be 400 MEUR according to DLMI Nordic Pharma Insights.

"Newbury is a start-up with high ambitions and we are rapidly growing our portfolio within our focus areas of oncology, rare diseases and neurology. We want to be known to make a difference within these therapeutic areas" says Karl Karlsson Founder & Chairman

## For more information, contact:

Lars Minor, CEO lars.minor@newburypharma.com

Mobile: +46 72-377 3005

www.newburypharma.com

## **About Newbury Pharmaceuticals**

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury Pharmaceuticals wants to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging its experience and extensive international network whereby Newbury can offer strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Press Release 10 December 2021 14:00:00 CET



## **Attachments**

Newbury Pharmaceuticals is strengthening its oncology portfolio